On Tuesday, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) opened lower -3.52% from the last session, before settling in for the closing price of $10.22. Price fluctuations for GLUE have ranged from $2.95 to $12.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 61.76% at the time writing. With a float of $46.18 million, this company’s outstanding shares have now reached $61.38 million.
Let’s look at the performance matrix of the company that is accounted for 133 employees. In terms of profitability, gross margin is 75.54%, operating margin of -543.6%, and the pretax margin is -501.56%.
Monte Rosa Therapeutics Inc (GLUE) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Monte Rosa Therapeutics Inc is 24.83%, while institutional ownership is 68.58%. The most recent insider transaction that took place on Oct 28 ’24, was worth 869,240. In this transaction 10% Owner of this company sold 89,990 shares at a rate of $9.66, taking the stock ownership to the 2,007,948 shares. Before that another transaction happened on Oct 29 ’24, when Company’s 10% Owner sold 67,905 for $9.16, making the entire transaction worth $621,801. This insider now owns 1,573,453 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 61.76% per share during the next fiscal year.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
Check out the current performance indicators for Monte Rosa Therapeutics Inc (GLUE). In the past quarter, the stock posted a quick ratio of 6.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit 0.18 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) saw its 5-day average volume 1.61 million, a positive change from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 83.80%. Additionally, its Average True Range was 0.82.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 71.40%, which indicates a significant decrease from 74.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.37% in the past 14 days, which was lower than the 141.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.16, while its 200-day Moving Average is $5.78. Nevertheless, the first resistance level for the watch stands at $10.35 in the near term. At $10.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.12. If the price goes on to break the first support level at $9.58, it is likely to go to the next support level at $9.30. The third support level lies at $8.81 if the price breaches the second support level.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
There are currently 61,437K shares outstanding in the company with a market cap of 605.76 million. Presently, the company’s annual sales total 0 K according to its annual income of -135,350 K. Last quarter, the company’s sales amounted to 9,220 K and its income totaled -23,860 K.
